2023
Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisClinical trial design for non-muscle-invasive bladder cancer
Tan W, Hall E, Kamat A, Kelly J. Clinical trial design for non-muscle-invasive bladder cancer. Nature Reviews Urology 2023, 20: 575-576. PMID: 37328547, DOI: 10.1038/s41585-023-00789-0.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCystectomyHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsBacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal?
Tan W, Grajales V, Bree K, Li R, Nogueras‐Gonzalez G, Navai N, Dinney C, Kamat A. Bacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal? BJU International 2023, 132: 384-386. PMID: 37246493, DOI: 10.1111/bju.16087.Peer-Reviewed Original Research
2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrencePathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
Thompson J, Sridhar A, Tan W, Freeman A, Haider A, Allen C, Moore C, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs T, Nathan S, Kelly J, Sooriakumaran P. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. Journal Of Urology 2019, 201: 1134-1143. PMID: 30730409, DOI: 10.1097/ju.0000000000000135.Peer-Reviewed Original ResearchConceptsSalvage robot-assisted radical prostatectomyRobot-assisted radical prostatectomyPositive surgical marginsSalvage prostatectomyRadical prostatectomySensitivity of magnetic resonance imagingField recurrenceMagnetic resonance imagingInfield recurrenceSurgical marginsHigher risk of positive surgical marginsGleason 3+3 diseasePrimary robotic assisted radical prostatectomyRisk of positive surgical marginsMagnetic resonance imaging concordancePositive surgical margin ratePartial ablationSalvage radical prostatectomyMagnetic resonance imaging sensitivityResonance imagingSurgical margin rateRisk of recurrenceCharacteristics of recurrenceProstatectomy histopathologyHigh-intensity focused ultrasound
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyRadiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measures
2016
Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium
Hussein A, Saar M, May P, Wijburg C, Richstone L, Wagner A, Wilson T, Yuh B, Redorta J, Dasgupta P, Khan M, Menon M, Peabody J, Hosseini A, Gaboardi F, Mottrie A, Rha K, Hemal A, Stockle M, Kelly J, Maatman T, Canda A, Wiklund P, Guru K, Collaborators, Balbay M, Poulakis V, Woods M, Tan W, Kawa O, Pini G, Badani K, Ahmed Y. Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal Of Urology 2016, 197: 1427-1436. PMID: 27993668, DOI: 10.1016/j.juro.2016.12.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedCystectomyFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesRobotic Surgical ProceduresTime FactorsTreatment FailureUrinary Bladder NeoplasmsConceptsRobot-assisted radical cystectomyOncological failureRadical cystectomyOverall survivalDisease relapseEvaluate predictorsInternational Robotic Cystectomy ConsortiumCox proportional regression analysisPort site recurrenceKaplan-Meier methodLymph node removalOncologic surgical principlesPeritoneal carcinomatosisNodal involvementPredictors of diseaseLocal recurrenceSite recurrencePneumoperitoneum pressureCystectomyMultivariate analysisSurgical principlesPatientsMultivariate modelDiseaseRelapseAnalysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes
Tan W, Sridhar A, Ellis G, Lamb B, Goldstraw M, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes. Urologic Oncology Seminars And Original Investigations 2016, 34: 257.e1-257.e9. PMID: 26968561, DOI: 10.1016/j.urolonc.2016.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCystectomyFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeUrinary Bladder NeoplasmsConceptsRecurrence free survivalCancer-specific survivalOpen radical cystectomyORC cohortOverall survivalRadical cystectomySpecific survivalNo significant differenceOncological outcomesSignificant differenceOpen radical cystectomy casesPositive surgical margin rateIntracorporeal robot-assisted radical cystectomyRobotic-assisted radical cystectomyRobot-assisted radical cystectomyEarly oncologic outcomesPreoperative chemotherapy useSurgical margin rateLymph node yieldMedian follow-upKaplan-Meir analysisCox regression analysisIntracorporeal urinary diversionRecurrence patternsPT0 status